Hexarelin Dosage, Protocol, and Reconstitution Guide

Hexarelin

Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) that activates the growth hormone secretagogue receptor and produces a strong growth hormone (GH) response. Human studies confirm potent GH-releasing activity, while also showing that Hexarelin can influence prolactin, ACTH, and cortisol under some conditions.

How Hexarelin Works

GHSR Activation → GH Secretory Pulse ↑ → GH / IGF-1 Pathway Signaling

Hexarelin is a synthetic growth hormone secretagogue that stimulates GH release through growth hormone secretagogue receptor signaling at the pituitary and hypothalamic level. Human studies demonstrate a strong GH response, although endocrine effects are not limited exclusively to GH.

Potent synthetic growth hormone-releasing peptide studied in humans.

Produces a strong, dose-dependent GH response.

Can also influence prolactin, ACTH, and cortisol depending on dose and administration pattern.

Repeated exposure may alter the magnitude of the acute GH response.

Hexarelin Research Protocol

5 mg vial + 3.0 mL BAC Water → 1 unit = 16.7 mcg → Strong GH Pulse

Standard Setup

Vial 5 mg

Water 3.0 mL bacteriostatic water

Concentration 1.67 mg/mL

Conversion 1 unit = 16.7 mcg

Weeks 1–2

Start Phase

Dose100 mcg

Units6 units

Volume0.06 mL

Weeks 3–4

Build Phase

Dose150 mcg

Units9 units

Volume0.09 mL

Weeks 5–6

Peak Phase

Dose200 mcg

Units12 units

Volume0.12 mL

Weeks 7–8

Peak Phase

Dose250 mcg

Units15 units

Volume0.15 mL

Protocol Details

FrequencyOnce daily

TimingBefore bed (fasted preferred)

Cycle Length6–8 weeks

Research context:
The dose progression above reflects a commonly discussed research/community framework rather than an established clinical titration schedule. Human Hexarelin studies have generally used weight-based dosing, and published research does not establish a universal 100–250 mcg progression.

Higher-Dose Research Context

Dose-Response Findings

Human research demonstrates that Hexarelin produces a dose-dependent GH response.

Increasing exposure can also increase prolactin and cortisol responses under some conditions.

Higher dosing should therefore not automatically be interpreted as producing a better overall endocrine response.

Published research does not establish a standardized "advanced" Hexarelin dose or prove that intermittent community dosing schedules prevent receptor desensitization.

How to Use Hexarelin (Timing & Injection)

Use StyleGH pulse optimization

Research TimingBefore bed (fasted)

Research Frequency1x daily

RouteSubcutaneous

Injection Notes

Best taken fasted for cleaner GH signaling

Common sites: abdomen, thigh, upper arm

Rotate injection sites regularly

Reconstitution & Dosing (5 mg Vial)

Vial5 mg

Water3.0 mL

Concentration1.67 mg/mL

Conversion1 unit = 16.7 mcg

Dose Reference

6 units ≈ 100 mcg

9 units ≈ 150 mcg

12 units ≈ 200 mcg

15 units ≈ 250 mcg

Reconstitution Steps

Draw 3.0 mL bacteriostatic water

Inject slowly down vial wall

Gently swirl (do not shake)

Refrigerate immediately

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (Unmixed)

Store refrigerated (2–8°C) for regular use

Freeze at −20°C (−4°F) for long-term storage

Keep sealed, dry, and protected from light

Avoid heat, moisture, and repeated temperature changes

Estimated shelf life: ~12–24 months refrigerated, longer if frozen

Reconstituted (Mixed)

Refrigerate at 2–8°C (36–46°F)

Do not freeze after mixing

Use within ~3–4 weeks

Avoid shaking or agitation

Discard if cloudy, discolored, or particles appear

Best Practice

Handling

Use sterile technique when reconstituting and drawing doses. Limit air exposure and keep vial sealed between uses.

Temperature

Return to refrigeration immediately after use. Avoid leaving at room temperature for extended periods.

Storage note:
Stability depends on formulation, purity, storage conditions, and the specific product being used. Follow manufacturer or pharmacy storage instructions when available rather than assuming a universal shelf life for lyophilized or reconstituted Hexarelin.

Research Cycle Length & Time Between Cycles

GH Secretagogue Research → Monitor Response → Reassess → Continue or Pause

Research Cycle Length

Typical6–8 weeks

Established Cycle Length No standardized cycle established

Human Research Repeated administration has been studied for up to 16 weeks

Time Between Cycles

Break4–6 weeks

Response Repeated exposure may alter the acute GH response

Established Off-Cycle No evidence-based off-cycle duration established

Reassessment can include GH / IGF-1 response, endocrine markers, tolerability, and whether the original research goal remains relevant.

What the research actually shows:
Human studies demonstrate that repeated Hexarelin exposure can change the magnitude of the GH response. However, this does not establish a required 6–8 week cycle, a 4–6 week receptor-reset period, or a specific schedule proven to prevent desensitization.

Human Clinical Research

Dose-Response Research

Population Healthy adult men

Administration Intravenous Hexarelin

Studied Range Up to 1 mcg/kg

Finding Strong dose-dependent GH response

Subcutaneous Human Research

Administration Subcutaneous

Studied Dose 1.5 mcg/kg

Frequency 2–3x daily in short-term research

Both schedules increased 24-hour GH secretion primarily by increasing GH secretory burst mass.

Short-term administration did not significantly increase 24-hour IGF-1, prolactin, ACTH, or cortisol in this study.

Other Endocrine Effects

Acute human studies have documented prolactin responses following Hexarelin administration.

ACTH and cortisol increases have also been demonstrated under some study conditions.

These findings show that Hexarelin is not completely selective for growth hormone release.

Important research distinction:
Human studies confirm that Hexarelin can strongly stimulate GH release, including after subcutaneous administration. However, published studies used specific weight-based research protocols and do not establish the fixed 100–300 mcg community protocols commonly discussed for body composition, recovery, or anti-aging purposes.

Monitoring During Research

GH / IGF-1 response

Prolactin

ACTH / cortisol when clinically relevant

Glucose-related markers during longer exposure

Fluid retention or edema

Injection-site tolerance

Why monitoring matters:
Hexarelin's endocrine activity is not limited exclusively to GH. Human studies have demonstrated effects on prolactin and the ACTH/cortisol axis under some conditions.

Benefits

Potent GH-releasing activity demonstrated in human studies

Can increase 24-hour GH secretion with repeated subcutaneous administration

GH / IGF-1 signaling is involved in tissue maintenance, metabolism, and body-composition pathways

Additional cardiovascular effects have been investigated experimentally, but clinical relevance remains uncertain

Potential Side Effects

Water retention

Increased cortisol or prolactin

Injection site irritation

Desensitization with prolonged use

Combination Research

GHRP Signaling + GHRH Signaling → Amplified GH Response

GHRH + Hexarelin

Human research demonstrates that combining a GHRH stimulus with low-dose Hexarelin can produce a substantially larger GH response than either pathway alone.

This supports the biological rationale for studying GHRH-pathway compounds alongside GHRPs.

Important distinction:
Human studies support synergy between Hexarelin and GHRH. This does not establish the safety or effectiveness of specific community peptide stacks such as Hexarelin + CJC-1295 NO DAC or combinations involving IGF-1 analogs.

Important Notes

Human studies demonstrate potent growth hormone-releasing activity.

Hexarelin acts through growth hormone secretagogue receptor signaling and can interact synergistically with the GHRH pathway.

Repeated exposure may reduce the magnitude of the acute GH response, but a required cycling schedule has not been established.

Human research has also documented effects on prolactin, ACTH, and cortisol under some study conditions.

Published research does not establish a specific off-cycle period or prove that scheduled breaks prevent desensitization.

Community dosing and cycling protocols should be distinguished from protocols actually studied in humans.

Important Disclaimer

Hexarelin is not FDA-approved for therapeutic use. Published human studies have investigated its endocrine effects, but common peptide-community dosing, cycling, and combination protocols have not been established as approved clinical treatment regimens. This content is for educational purposes only.

Research & References

Primary Research

• Imbimbo BP, Mant T, Edwards D, et al. Growth Hormone-Releasing Activity of Hexarelin in Humans: A Dose-Response Study. Eur J Clin Pharmacol. 1994.
• Popovic V, Micic D, Djurovic M, et al. Absence of Desensitization by Hexarelin to Subsequent GH Releasing Hormone-Mediated GH Secretion in Patients with Anorexia Nervosa. Clin Endocrinol. 1997.
• Massoud AF, Hindmarsh PC, Matthews DR, Brook CG. The Effect of Repeated Administration of Hexarelin, a Growth Hormone Releasing Peptide, and Growth Hormone Releasing Hormone on Growth Hormone Responsivity. Clin Endocrinol. 1996.
• Arvat E, et al. Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue, in Humans: Comparison and Interactions with Hexarelin. J Clin Endocrinol Metab. 2001.
• Rahim A, O'Neill P, Shalet SM. The Effect of Body Composition on Hexarelin-Induced Growth Hormone Release in Normal Elderly Subjects. Clin Endocrinol. 1998.

Research Note: The clinical studies above establish Hexarelin's growth hormone secretagogue activity and dosing/response relationships in controlled research settings. Specific self-administration protocols, cycle lengths, and injection frequencies described on this page are drawn from compounding-community practice and are not directly validated by the cited trials.

Hexarelin Guide → Peptide Directory →